Breakthrough in Chinese Biopharmaceutical Industry: $800 Million Down Payment Received

In the realm of innovative pharmaceuticals, China continues to witness remarkable leaps forward. Following Kangfang Biotech's recent acquisition of a $500 million down payment, Baili Pharm achieved its own moment of glory on March 10th, securing an astounding $800 million down payment from Bristol-Myers Squibb (BMS). This significant milestone is attributed to their BL-B01D1 project, a revolutionary EGFR×HER3 bispecific antibody-drug conjugate (ADC). The immense wealth and recognition not only showcase the research capabilities of Chinese pharmaceutical enterprises but also serve as a testament to international acknowledgment of China's innovative drugs.

The Collaboration:

On December 11th, 2023, Baili Pharm entered into an exclusive licensing and collaboration agreement with BMS, granting BMS exclusive development and commercialization rights for BL-B01D1 globally (excluding mainland China). As part of the agreement, BMS committed an upfront payment of up to $800 million, along with potential milestone payments of up to $7.1 billion. This collaboration aims to address the issue of HER3 resistance in EGFR-targeted therapies, offering promising therapeutic benefits to patients.

BL-B01D1 and Clinical Trials:

BL-B01D1, the world's first bispecific antibody-drug conjugate targeting EGFR and HER3, combines a small molecule toxin derived from Baili Pharm's independently developed ED04 with a DAR value of 8. The drug is currently undergoing Phase I clinical trials (BL-B01D1-LUNG101) to evaluate its safety and efficacy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). Encouraging efficacy and safety data were presented during the 2023 ESMO Congress, where BL-B01D1 demonstrated a median progression-free survival (PFS) of 6.9 months for EGFR-mutant patients and 5.2 months for EGFR wild-type patients among the evaluated NSCLC cohort. The overall objective response rate (ORR) for the entire cohort of 102 evaluable NSCLC patients was 51%. The most common treatment-related adverse events (TRAE) of Grade 3 or higher included anemia, leukopenia, neutropenia, and thrombocytopenia, with no cases of interstitial lung disease (ILD) reported.

The Promise of Bispecific ADCs:

Bispecific antibody-drug conjugates (ADCs) represent a novel biopharmaceutical technology that combines the characteristics of bispecific antibodies and ADCs. Bispecific antibodies have the ability to simultaneously recognize two different antigens or two distinct epitopes of the same antigen, while ADCs enable the precise targeting of toxic chemotherapy drugs to tumor cells through stable linkers. Although no bispecific ADCs have been approved for market use globally, several products are currently in clinical development. Chinese pharmaceutical companies have shown active involvement in this field, with multiple bispecific ADCs under development.

The $800 million down payment received by Baili Pharm for their BL-B01D1 project not only highlights the scientific prowess of Chinese pharmaceutical companies but also signifies international recognition of China's innovation in drug development. As the first bispecific ADC targeting EGFR and HER3, BL-B01D1 shows promising efficacy in overcoming HER3 resistance in EGFR-targeted therapies. With ongoing clinical research and technological advancements, bispecific ADCs have the potential to become a significant modality in future cancer treatments. The progress and pipeline of bispecific ADCs demonstrate the vibrancy of this field, with various companies actively engaged in developing innovative therapies.